Lorcainide hydrochloride, Na+/K+ ATPas inhibitor (ab141821)

Overview

  • Product name

    Lorcainide hydrochloride, Na+/K+ ATPas inhibitor
  • Description

    Voltage-gated Na+ channel blocker. Inhibits Na+/K+ ATPas.
  • Biological description

    Voltage-gated Na+ channel blocker. Inhibits Na+/K+ ATPase (IC50 = 34 μM). Shows anti-arrhythmia and neuroprotective effects in vivo.
  • Purity

    > 99%
  • CAS Number

    58934-46-6
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    N-(4-Chlorophenyl)-2-phenyl-N-(1-propan-2-ylpiperidin-4-yl)acetamide hydrochloride
  • Molecular weight

    407.40
  • Molecular formula

    C22H27ClN2O.HCl
  • PubChem identifier

    6917855
  • Storage instructions

    Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in water to 50 mM, in DMSO to 50 mM and in ethanol to 50 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CC(C)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C(=O)CC3=CC=CC=C3.Cl
  • Source

    Synthetic

  • Research areas

Images

  • Lorcainide HCl inhibits NaV1.7 channels expressed in HEK293 cells.

    A: Time course of current reversible inhibition by 50 µM Lorcainide HCl (ab141821). Currents were elicited by a voltage ramp from a holding potential of -100 mV to 60 mV (30 ms) delivered every 10 seconds. B: Example traces of current response to voltage ramp stimulation before and during 50 µM Lorcainide HCl application.

References

This product has been referenced in:

  • Almotrefi AA  et al. Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+ -K+ ATPase. Can J Physiol Pharmacol 77:866-70 (1999). Read more (PubMed: 10593659) »
  • Lynch JJ  et al. Sodium channel blockers reduce oxygen-glucose deprivation-induced cortical neuronal injury when combined with glutamate receptor antagonists. J Pharmacol Exp Ther 273:554-60 (1995). Read more (PubMed: 7714811) »
  • Sheldon RS  et al. Antiarrhythmic drugs and the cardiac sodium channel: current models. Clin Chem 35:748-54 (1989). Read more (PubMed: 2541948) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141821.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up